PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
PHXM was delisted on the 8th of March, 2024.
10 hedge funds and large institutions have $101M invested in PHAXIAM Therapeutics S.A.. American Depositary Shares in 2017 Q4 according to their latest regulatory filings, with 10 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
14.84% more ownership
Funds ownership: 0% → 14.84% (+15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$73M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$14.8M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$14.8M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.83M |
| 5 |
Millennium Management
New York
|
+$1.03M |
Top Sellers
PHXM Hedge Fund Activity: Q4 2017 in Review
10 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) for Q4 2017, worth a combined $101M.
Buyers outnumbered sellers: 10 funds opened new PHXM positions and 0 closed out — a net gain of 10 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $73M.
- 10 institutional investors held PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) as of Q4 2017, up from 0 in Q3 2017.
- Funds reported $101M of PHAXIAM Therapeutics S.A.. American Depositary Shares stock for Q4 2017.
- 10 funds opened new PHAXIAM Therapeutics S.A.. American Depositary Shares positions in Q4 2017 and 0 closed out, a net change of +10 holders.
- The largest PHAXIAM Therapeutics S.A.. American Depositary Shares buyer in Q4 2017 was Baker Bros. Advisors, an estimated $73M added.
Based on aggregated 13F filings for Q4 2017.